TFF PHARMACEUTICALS, INC.: 10-Q filed 2019-12-09
What TFF PHARMACEUTICALS, INC. reported in its quarterly report filed 2019-12-09 (fiscal Q3 2019): 22 published measures, 74 facts as tagged in accession 0001213900-19-025650.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2019-12-09
- Fiscal period
- fiscal Q3 2019
- Accession
- 0001213900-19-025650 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TFF PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 11,032,759 | USD | |
| At 2018-12-31 | 10,401,504 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 2,188,331 | USD | |
| At 2018-12-31 | 1,156,995 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | -10,839,769 | USD | |
| At 2019-06-30 | -7,513,815 | USD | |
| At 2019-03-31 | -5,524,330 | USD | |
| At 2018-12-31 | -3,241,462 | USD | |
| At 2018-09-30 | -2,239,445 | USD | |
| At 2018-06-30 | -1,496,838 | USD | |
| At 2018-03-31 | -267,501 | USD | |
| At 2017-12-31 | -1,833 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 10,550,569 | USD | |
| At 2018-12-31 | 10,261,671 | USD | |
| At 2018-09-30 | 11,136,040 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -2,838,303 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -7,208,038 | USD | 273 |
| 2018-07-01 to 2018-09-30 | -585,215 | USD | 92 |
| 2018-01-24 to 2018-09-30 | -2,969,875 | USD | 250 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | -6,909,328 | USD | 273 |
| 2018-01-24 to 2018-09-30 | -1,343,389 | USD | 250 |
| 2018-01-01 to 2018-01-23 | -1,833 | USD | 23 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | 7,198,226 | USD | 273 |
| 2018-01-24 to 2018-09-30 | 12,479,429 | USD | 250 |
| 2018-01-01 to 2018-01-23 | -1,833 | USD | 23 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | -11,050,224 | USD | |
| At 2018-12-31 | -3,842,186 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | 400,000 | shares | 273 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -229,016 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 378,607 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 62,106 | USD | 92 |
| 2018-01-24 to 2018-09-30 | 1,235,946 | USD | 250 |
| 2018-01-01 to 2018-09-30 | 1,235,946 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -2,864,168 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -7,275,737 | USD | 273 |
| 2018-07-01 to 2018-09-30 | -606,086 | USD | 92 |
| 2018-01-24 to 2018-09-30 | -3,003,143 | USD | 250 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 10,570,866 | USD | |
| At 2018-12-31 | 10,273,736 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 691,105 | USD | |
| At 2018-12-31 | 428,645 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 2,864,168 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 7,275,737 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 606,086 | USD | 92 |
| 2018-01-24 to 2018-09-30 | 3,003,143 | USD | 250 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 2,563,528 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 5,554,046 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 140,167 | USD | 92 |
| 2018-01-24 to 2018-09-30 | 759,355 | USD | 250 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 4,000,000 | shares | |
| At 2018-12-31 | 4,000,000 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 206,455 | USD | |
| At 2018-12-31 | 596,724 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -2,838,303 | USD | 92 |
| 2019-04-01 to 2019-06-30 | -2,186,920 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -2,182,815 | USD | 90 |
| 2018-07-01 to 2018-09-30 | -585,215 | USD | 92 |
| 2018-04-01 to 2018-06-30 | -2,117,160 | USD | 91 |
| 2018-01-24 to 2018-03-31 | -267,501 | USD | 67 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -3,096,938 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -7,976,914 | USD | 273 |
| 2018-07-01 to 2018-09-30 | -804,713 | USD | 92 |
| 2018-01-24 to 2018-09-30 | -3,475,391 | USD | 250 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 300,640 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 1,721,691 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 465,919 | USD | 92 |
| 2018-01-24 to 2018-09-30 | 2,243,788 | USD | 250 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 25,865 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 67,699 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 20,871 | USD | 92 |
| 2018-01-24 to 2018-09-30 | 33,268 | USD | 250 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | 181,307 | USD | 273 |
| 2018-01-24 to 2018-09-30 | 426,845 | USD | 250 |
| 2018-01-01 to 2018-01-23 | -1,833 | USD | 23 |
Inspect the source
- Entity
- TFF PHARMACEUTICALS, INC. / CIK 0001733413
- Captured
- 2026-09-21T17:25:24.015Z
- SEC response SHA-256
831f4629fefc666a0d697443131c6e51c7c7a82a58f012a492b81a69560d76f0
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001733413.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))